

ROTTAPHARM|MADAUS LICENSES CANADIAN RIGHTS FOR SANCTURA XR™ TO ALLERGAN INC.

Monza, May 22, 2008 — Rottapharm|Madaus Group today announced the signing of a License Agreement with Allergan Inc., a Canadian affiliate of Allergan, Inc., granting Allergan the right to market SANCTURA XR™ (trospium chloride extended release preparation) throughout Canada. Rottapharm|Madaus jointly granted the rights along with Indevus Pharmaceuticals, Inc. as required by a prior agreement between Rottapharm|Madaus and Indevus. Rottapharm|Madaus and Indevus will share equally in the proceeds from the license transaction. Under the terms of the agreement, Allergan will pay up to \$9 million to each of Rottapharm|Madaus and Indevus, including a \$7 million up-front license fee and up to \$2 million in sales threshold milestone payments. Allergan will be responsible for all regulatory and marketing activities in Canada.

“We are pleased to have licensed the Canadian rights for SANCTURA XR™ to Allergan, a highly competent organization” stated Prof. Luigi Rovati, chairman of Rottapharm|Madaus “Within the current year, we are expecting Marketing Authorizations in order to launch the product in several European countries, where we own full marketing rights. Furthermore we continue to pursue opportunities to obtain marketing partners for SANCTURA XR™ in Japan, Korea and China, where we share the rights with Indevus.”

SANCTURA XR™ is indicated for the once-daily treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. SANCTURA XR™ was approved by the U.S. Food and Drug Administration (FDA) in August 2007, but has not yet been approved for sale and marketing in Canada. In October 2007, Allergan, Inc. obtained the U.S. rights to SANCTURA® (a twice-daily preparation) and SANCTURA XR™ through its acquisition of Esprit Pharmaceuticals and began selling SANCTURA XR™ in the U.S. in January 2008. Indevus previously licensed rights to SANCTURA XR™ throughout the rest of the world to Rottapharm|Madaus, except for Canada, Japan, Korea and China, where Indevus and Rottapharm|Madaus agreed to jointly license rights to SANCTURA XR™ to third party partners.

About Trospium Chloride

Trospium chloride for OAB/urinary incontinence was originally developed by Rottapharm|Madaus and is currently marketed as a twice-daily preparation by Rottapharm|Madaus and several Rottapharm|Madaus licensees as a prescription drug product in Europe and other territories, with different trade marks (SPASMOLYT®, CERIS®, URAPLEX®, REGURIN®, SANCTURA®, TROSEC®). It belongs to a class of anticholinergic compounds known as muscarinic receptor antagonists. These compounds relax detrusor smooth muscle tissue found in the bladder, thus decreasing bladder contractions. Overactive or unstable detrusor muscle function is believed to be the cause of OAB. Trospium chloride possess a quaternary ammonium structure that may be instrumental in the low incidence of CNS side-effects. At therapeutic concentrations in vitro, trospium chloride does not interact with drugs metabolized by the Cytochrome P-450 system, a metabolic pathway commonly associated with drug-drug interactions, and the majority of the absorbed dose is excreted largely unchanged into the urine. Patients

who have urinary retention, gastric retention, uncontrolled narrow-angle glaucoma or hypersensitivity to tropsium chloride should not use tropsium chloride.

About Rottapharm|Madaus

Rottapharm is an Italian multinational pharmaceutical company, headquartered in Monza, with branches in over 80 countries worldwide. Since its inception, Rottapharm has been primarily focusing on research. R&D activities are currently engaged in different therapeutic areas: gastroenterology, bronchopneumology, psychiatry, rheumatology, urology, gynaecology, cardiovascular, oncology, and recently in the personal care and nutraceutical segment. In August 2007, Rottapharm acquired the German pharmaceutical Group of Companies Madaus. This acquisition represents an important turning point for Rottapharm in terms of R&D synergies and marketing growth. After the acquisition of Madaus, Rottapharm has combined its well-known brands such as DONA[®], EXTRANASE[®], FORTILASE[®], EPINITRIL[®], ESTROMINERAL[®] and SAUGELLA[®] with 12 new leading brands including AGIOLAX[®], REPARIL[®], LEGALON[®], TROMALYT[®] and BEN-U-RON[®], thus entering new pharmaceutical market segments. Rottapharm|Madaus headquarters and research center are in Monza (Italy) with seven manufacturing sites in the world: Confienza (Italy), Dublin (Ireland), Wiehl (Germany), Troisdorf (Germany), Barcelona (Spain), Lisbon (Portugal) and Goa (India).